Predictmedix Inc. announced substantial progress in its ongoing partnership with a Indonesian university, as it advances through the validation process for regulatory approval of its AI-product suite as a medical device in Indonesia. Additionally, Predictmedix has actively engaged with government officials from the technology sector to explore the extensive healthcare applications of its Safe Entry solution at a scalable level. Over the past three weeks, Predictmedix has had the privilege of working closely with government officials with the aim to explore diverse applications using the company's AI products and technology which can integrate seamlessly into pre-existing systems for rapid scalability.

Furthermore, Predictmedix's ongoing partnership with key Indonesian university plays a pivotal role in its commercialization plan throughout lucrative Asian regions. Through comprehensive testing and analysis, the company aims to demonstrate the efficacy and accuracy of its AI technology and products in diagnosing a broad range of medical conditions and screening for key vitals as part of standard operating procedures in healthcare. Predictmedix's partnership with the university has been essential in advancing its AI-powered technology applications and providing access to diverse patient populations, enabling real-world validation of its cutting-edge solutions.

Obtaining regulatory approval for medical devices is an integral aspect of any product prior to being commercialized in healthcare settings. As part of the Predictmedix's commercialization plan, regulatory approval for the company's suite of AI-products in Indonesia is underway. The company is committed to meeting rigorous industry standards and regulations and is confident in obtaining regulatory approval, building on its track record of successful regulatory compliance.